Tweede Supplement op het Prospectus d.d. 29 maart 2023 maart 29, 20230OpmerkingenTweede Supplement op het Prospectus d.d. 29 maart 2023 Read More
Derde Supplement op het Prospectus d.d. 29 maart 2023 maart 29, 20230OpmerkingenDerde Supplement op het Prospectus d.d. 29 maart 2023 Read More
Vierde Supplement op het Prospectus d.d. 29 maart 2023 maart 29, 20230OpmerkingenVierde Supplement op het Prospectus d.d. 29 maart 2023 Read More
Vijfde Supplement op het Prospectus d.d. 29 maart 2023 maart 29, 20230OpmerkingenVijfde Supplement op het Prospectus d.d. 29 maart 2023 Read More
New Shares Prospectus – March 29, 2023 maart 29, 20230OpmerkingenProspectus for the admission to trading on Euronext Brussels of up to 1,885,000,000 new shares Read More
First Supplement to the Prospectus of March 29, 2023 maart 29, 20230OpmerkingenFirst Supplement to the Prospectus of March 29, 2023 Read More
Second Supplement to the Prospectus of March 29, 2023 maart 29, 20230OpmerkingenSecond Supplement to the Prospectus of March 29, 2023 Read More
Third Supplement to the Prospectus of March 29, 2023 maart 29, 20230OpmerkingenThird Supplement to the Prospectus of March 29, 2023 Read More
Fourth Supplement to the Prospectus of March 29, 2023 maart 29, 20230OpmerkingenFourth Supplement to the Prospectus of March 29, 2023 Read More
Fifth Supplement to the Prospectus of March 29, 2023 maart 29, 20230OpmerkingenFifth Supplement to the Prospectus of March 29, 2023 Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS maart 24, 20230OpmerkingenEN NL Read More
Oxurion Issues EUR 2.8 million in Bonds for Tranche 1 (A) of Funding Program with Atlas Special Opportunities LL maart 20, 20230OpmerkingenEN Read More
Oxurion Provides Update on Recruitment for KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema and Announces Board Changes maart 14, 20230OpmerkingenEN Read More
Beoordelingsverslag van de commissaris aan de Raad van Bestuur – 8 march 2023 maart 8, 20230OpmerkingenAuditor's Report to the Board of Directors (NL only) Read More
Beoordelingsverslag van de commissaris aan de Raad van Bestuur – 8 march 2023 maart 8, 20230OpmerkingenAuditor's Report to the Board of Directors (NL only) Read More
Speciaal verslag van de Raad van Bestuur – 7 maart 2023 maart 7, 20230OpmerkingenSpeciaal verslag van de Raad van Bestuur Read More
Board of Directors Special Report – March 7, 2023 maart 7, 20230OpmerkingenSpecial report of the Board of Directors Read More
Oxurion Announces Subscription Agreement with Atlas Providing the Company with Up To €20 Million in Funding maart 2, 20230OpmerkingenEN Read More
